Compare Bristol-Myers Squibb Co (BMY) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Lowe`s Companies Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Lowe`s Companies Inc trades at $209.07 (market cap $116.45B). The key difference: Bristol-Myers Squibb Co and Lowe`s Companies Inc are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | LOW | |
|---|---|---|
Market Cap | $116.30B | $116.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $287.39 |
52-Week Low | $42.60 | $206.62 |
Enterprise Value | $152.24B | $158.20B |
Dividend Yield | 4.42% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Lowe's (LOW) trades at $207.70, down 1.86% on the day, with a bearish technical signal from moving averages but oversold short-term RSI. The company maintains solid profitability with a 7.51% net margin and has beaten EPS estimates for three consecutive quarters. Revenue declined to $83.67B in 2025, though cash flow from operations improved to $9.63B. Recent news highlights Lowe's dividend growth strategy, with the quarterly payout rising to $1.25.
The outlook is mixed: strong analyst consensus (60.79% buy ratings) and a $260.88 price target suggest upside, but technical weakness and high debt levels pose risks. Earnings stability and dividend growth support long-term value, though housing market sensitivity and competitive pressures remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
